Associate Professor
Strategic program(s):
Biography
Peter Seevinck graduated Biomedical Engineering at the Eindhoven University of Technology in 2005. In 2009, he received his PhD in Medical Imaging at Utrecht University after defending his thesis entitled “Multimodal imaging of holmium-loaded microspheres for internal radiation therapy”.
Currently Peter is appointed Associate Professor (UHD) at the Image Sciences Institute in the Imaging Division of UMC Utrecht. He acts as a coordinator and lecturer in several courses in the field of MRI. His research is focusing on the development and clinical introduction of novel MR imaging methods and advanced machine learning algorithms for minimally invasive and safe personalized image-guided diagnosis and therapy. Examples of these novel approaches include MRI-guided device visualization for cardiac stem cell therapy and brachytherapy, MRI-only radiotherapy treatment planning for more efficient and shorter treatment workup and MRI-based bone imaging (BoneMRI), reducing radiation burden and workflow complexity. He has >50 publications in this field, and has been awarded several (personal) scientific and valorisation grants including VENI (interventional MRI), IMDI ZonMw (MRI-based radiotherapy planning), TTW Take-off phase I and II (commercialization of BoneMRI) and TTW Smart Industry (Deep learning-based image synthesis for orthopedics), NWO KIEM (BoneMRI in the shoulder) and Eurostars (additive manufacturing for orthopedics).
Peter Seevinck is co-founder of MRIguidance B.V., a company that commercializes BoneMRI, the first medical imaging technique that visualizes both bone and soft tissue, without the need for hazardous radiation. BoneMRI renders MRI a one-stop-shop workflow both for diagnostic/prognostic purposes as well as for innovative surgical purposes (e.g. pre-operative planning, navigation, virtual/augmented reality and robotics). For the patient such a one-stop-shop approach could lead to less radiological examinations, less hospital visits and a lower radiation burden. “With the CE marking of BoneMRI in 2019 an important milestone has been reached, as this opens the door towards widespread usage for the benefit of the patient”.
